Outcome MeasureSafety / Adverse Events

SARA

Scale for the Assessment and Rating of Ataxia

1 Paper in Blossom

Outcome Data Across Studies

Reported results for SARA across 1 study with quantitative data.

Outcome data across 3 study arm–timepoint observations
SD
Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
2021Secondary
Ibogaine single dose(experimental)014———
Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
2021Secondary
Ibogaine single dose(experimental)0.1671413.7——
Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study
2021Secondary
Ibogaine single dose(experimental)1140.0——

Papers Using SARA

Open Accessindividual

Safety of ibogaine administration in detoxification of opioid dependent individuals: a descriptive open-label observational study

This open‑label study (n=14) of opioid‑dependent patients given a single 700 mg per 70kg dose of ibogaine‑HCl, treatment produced clinically relevant but reversible cardiac and cerebellar toxicity. The mean maximal QTc(F) prolongation was 95 ms, with 50% of participants exceeding 500 ms, accompanied by bradycardia and severe transient ataxia. Psychomimetic and withdrawal effects were generally manageable, and no torsades de pointes were observed.

Published
Journal
Addiction
Authors
Knuijver, T., Schellekens, A., Belgers, M., Donders, R., Kramers, C., Verkes, R. J.

Quick Facts

Full Name
Scale for the Assessment and Rating of Ataxia
Domain
Safety / Adverse Events
Papers Indexed
1
Score Range
0–40
Interpretation
Lower = better
All Measures